SALT
LAKE CITY, Sept. 24, 2024 /PRNewswire/
-- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the
"Company"), a molecular diagnostics company with a unique, patented
platform for the development of molecular diagnostic tests, today
announced Company representatives will be accompanying Utah Governor Cox and the Governor's Office of
Economic Opportunity, as part of the latest World Trade Center
(WTC) Utah trade mission to
South Korea and Japan from September
24-October 5.
Co-Dx will join the delegation for life sciences and innovation,
aiming to expand its international relationships. The company
announced the creation of a joint venture in India in 2017 called CoSara Diagnostics Pvt.
Ltd. and has also developed a robust portfolio of distributors,
partners and customers in more than 50 countries during the
pandemic years when Co-Diagnostics distributed millions of COVID-19
PCR tests globally. The WTC trade mission comes as Co-Dx is
strengthening global relationships in preparation for introducing a
new PCR diagnostic platform designed for at-home and point-of-care
use.
The itinerary for the trip includes visits with industry leaders
in a region of the world that the Company anticipates playing a
role in its future.
"Building a global network of relationships is vital as we
advance our mission of improving access to care for patients around
the world, increasing the availability and accessibility of
high-quality PCR diagnostics," said Dwight
Egan, Chief Executive Officer, Co-Diagnostics, Inc. "We are
pleased to be part of this prestigious trade mission and to help
further Utah's goals while
advancing our own important initiatives."
World Trade Center Utah is the official international business
promotion organization for the Governor's Office of Economic
Opportunity in the State of Utah
and conducts frequent trade missions around the world, connecting
Utah business to global
resources.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a
Utah corporation, is a molecular
diagnostics company that develops, manufactures and markets
state-of-the-art diagnostics technologies. The Company's
technologies are utilized for tests that are designed using the
detection and/or analysis of nucleic acid molecules (DNA or RNA).
The Company also uses its proprietary technology to design specific
tests for its Co-Dx PCR at-home and point-of-care platform and to
locate genetic markers for use in applications other than
infectious disease.
Forward-Looking Statements:
This press
release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995
(PSLRA) that are subject to a number of risks and uncertainties.
Forward-looking statements can be identified by words such as
"believes," "expects," "estimates," "intends," "may," "plans,"
"will" and similar expressions, or the negative of these words.
Such forward-looking statements are based on facts and conditions
as they exist at the time such statements are made and predictions
as to future facts and conditions. Forward-looking statements in
this release include statements regarding our preparation for
introducing a new PCR diagnostic platform designed for at-home and
point-of-care use and our efforts to advance our mission of
improving access to care for patients around the world and
increasing the availability and accessibility of high-quality PCR
diagnostics. Actual results may differ materially from those
contemplated or anticipated by such forward-looking statements.
Readers of this press release are cautioned not to place undue
reliance on any forward-looking statements. There can be no
assurance that any of the anticipated results will occur on a
timely basis or at all due to certain risks and uncertainties, a
discussion of which can be found in our Risk Factors disclosure in
our Annual Report on Form 10-K, filed with the Securities and
Exchange Commission (SEC) on March 14, 2024, and in our other
filings with the SEC. The Company does not undertake any obligation
to update any forward-looking statement relating to matters
discussed in this press release, except as may be required by
applicable securities laws.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-to-accompany-utah-governor-and-wtc-utah-on-trade-mission-to-south-korea-and-japan-302256743.html
SOURCE Co-Diagnostics
